Experimental Biotech Drug Benralizumab Reaches Final-Stage Clinical Trials

Experimental Biotech Drug Benralizumab Reaches Final-Stage Clinical TrialsOn Wednesday, AstraZeneca said it was proceeding to final-stage of clinical trials with its experimental biotech drug benralizumab. The drug is used for severe uncontrolled asthma.

MedImmune scientists in the Cambridge UK medical technology cluster have conducted a study. The findings of the study have contributed in the development of a possible new treatment for acute asthma.

According to a spokesperson for AZ's biologics R&D arm, the advancement in the field of the study is an honor to cross-border scientific teamwork culture in MedImmune.

Benralizumab is a monoclonal antibody fixes with a receptor that reduces eosinophils. Eosinophils are white blood cells that play a vital role in the cause and extremity of asthma and its side-effects.

MedImmune refers to emerging proofs which shows that for patients with higher number of eosinophil counts cure with an inhibitor for example, benralizumab.

"Benralizumab has the potential to address an important area of unmet medical need as there are currently limited treatment options available for patients with severe uncontrolled asthma", said William Mezzanotte, VP and head of Respiratory & Inflammation and Neuroscience in AstraZeneca's global medicines development unit.

The trial will review the effect of benralizumab on functioning of lungs, asthma symptoms and other measures taken to control asthma.